GEP-NET clinical trials at UCLA
1 research study open to eligible people
Showing trials for
RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
open to eligible people ages 18 years and up
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in…
Los Angeles, California and other locations
Our lead scientists for GEP-NET research studies include Martin S. Allen-Auerbach, MD.
Last updated: